Trefoil Therapeutics
Manufacturing · California, United States · 1-10 Employees
View Company Info for Free
Overview
Headquarters
6330 Nancy Ridge Dr Ste 103, San Diego, ...Phone Number
(858) 294-0401Website
www.trefoiltherapeutics.comRevenue
<$5 MillionIndustry
ZI Rank: 1
Signal Type
Jan
Feb
Mar
Apr
May
Jun
ZI Rank
2
1
1
1
1
1
About Trefoil Therapeutics
Trefoil Therapeutics is a clinical-stage biotechnology company dedicated to restoring sight for individuals suffering from corneal diseases. The company is advancing two products based on its lead candidate, TTHX1114, which targets both epithelial and endothelial corneal conditions through engineered Fibroblast Growth Factor (FGF1). Their offerings include an intracameral injection for endothelial decompensation and a topical formulation for epithelial damage. With a strong management team and significant research backing, Trefoil aims to provide innovative therapies for patients with limited treatment options.Explore more
Trefoil Therapeutics Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Trefoil Therapeutics your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Check if Trefoil Therapeutics has recently received funding, and reach out quickly before it becomes old news!
Check out if Trefoil Therapeutics is spiking on competitors!
Click to see if Trefoil Therapeutics had a recent Job posting/layoffs
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Earning: See what the market has to say on Trefoil Therapeutics recently announced quarterly report
Trefoil Therapeutics, which may be a good buyer, showed buying intent in Masked Content Topic
Congratulate Masked Content for being promoted to Masked Content at Trefoil Therapeutics
Funding: Get notified immidiatlly once Trefoil Therapeutics has new funding data
Product Launch: Get notified when Trefoil Therapeutics launches new products
Website visits: Recent activity has been detected on your website
Recommended Actions
Find VP level buyers at Trefoil Therapeutics
Find 2 more new buyers
Compare Similar Companies to Trefoil Therapeutics
Compare insights from companies similar to Trefoil Therapeutics, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Trefoil Therapeutics
<$5M
1-10
Private
$32.2M
2014
TT
Thomas TremblayHead Vice President, Clinical Development & of Clinical Operations
Company Profile Activity
Activity Insights
Trefoil Therapeutics is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
Trefoil Therapeutics is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about Trefoil Therapeutics.
Trefoil Therapeutics financials insights
Gather financial insights about Trefoil Therapeutics, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2016
Private Equity
$4.2M
2019
Series A
$28M
Trefoil Therapeutics Tech Stack
A closer look at the technologies used by Trefoil Therapeutics
See more technologies
Trefoil Therapeutics News & Media
New Trefoil Therapeutics’ Data Presented at ARVO Demonstrate that TTHX1114 Controls Edema in At-Risk Patients Undergoing Cataract Surgery
SAN DIEGO--(BUSINESS WIRE)--Trefoil Therapeutics today announced data presentations demonstrating the potential use of TTHX1114 to protect endothelial cells at the ARVO Meeting.Trefoil Therapeutics Announces TTHX1114 Data Presentations at the Annual Association for Research in Vision and Ophthalmology (ARVO) Meeting
SAN DIEGO--(BUSINESS WIRE)--Trefoil Therapeutics Announces TTHX1114 Data Presentations at the Annual Association for Research in Vision and Ophthalmology (ARVO) MeetingTrefoil Therapeutics Announces First Patient Dosed in Phase 1 Study of TTHX1114 for Treatment of Corneal Epithelial Defects
SAN DIEGO--(BUSINESS WIRE)--Trefoil Therapeutics Announces First Patient Dosed in Phase 1 Study of TTHX1114 for Treatment of Corneal Epithelial DefectsTrefoil Therapeutics Announces Positive TTHX1114 Phase 2 Study Data Showing Corneal Regeneration and Vision Recovery Following Descemet Stripping Only (DSO) Surgery
CHICAGO--(BUSINESS WIRE)--Trefoil Therapeutics today announced positive Phase 2 results for TTHX1114 in patients with Fuchs Endothelial Corneal Dystrophy.
Read more news
Top Manufacturing Companies
Top companies in Canada by revenue
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Trefoil Therapeutics
Sign Up For FreeTo access detailed company insights
Trefoil Therapeutics is a clinical-stage biotechnology company dedicated to restoring sight for individuals suffering from corneal diseases. The company is advancing two products based on its lead candidate, TTHX1114, which targets both epithelial and endothelial corneal conditions through engineered Fibroblast Growth Factor (FGF1). Their offerings... Read More
